Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Defactinib||Phase I||Actionable||In a Phase I trial, 31% (17/55) of KRAS-mutant patients with non-small cell lung cancer demonstrated progression-free survival at 12 weeks and one patient experienced a partial response and eight patients had stable disease as a best overall response when treated with Defactinib (VS-6063) (PMID: 31739184; NCT01778803).||31739184|